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Abstract: 
A method for the purification of Vi capsular polysaccharide produced during fermentation of Salmonella typhi was developed. A 
number of wild type isolates of S. typhi were obtained from National Institute of Cholera and Enteric Diseases (NICED) India and 
screened for their capacity to produce Vi. One isolate designated C6524 produced more Vi than any of the other isolates so was 
selected as a potential seed lot for vaccine production. The first step in the Vi purification process was to separate the S typhi cells 
from the crude Vi and this was achieved by crossflow microfiltration followed by diafiltration against high salt to assist passage of 
the Vi through the membrane into the permeate.  The next step was to precipitate the Vi which has a negative charge at neutral pH 
with the positively charged cetavlon. During this procedure most of the protein, nucleic acid and LPS impurities remained in 
solution and were easily separated from the precipitated Vi after washing of the precipitate with 20% ethanol.  The precipitated Vi 
was then dissolved in 60% ethanol. The Vi was then precipitated a second time by increasing the ethanol concentration to 75%, the 
precipitate was allowed to settle and the ethanol decanted, the Vi was then dissolved in water. To achieve satisfactory nucleic acid 
levels ammonium sulfate was added and the precipitate containing nucleic acid was removed by filtration. The purified Vi produced 
by this method met the WHO requirements for Vi polysaccharide vaccine with a high yield of Vi equating to low production costs 
and an affordable vaccine for communities living in typhoid endemic areas. 
© 2010 Published by Elsevier Ltd.
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1. Introduction 
Typhoid fever caused by Salmonella enterica serovar typhi (S. typhi) remains an important health problem in many 
parts of the world with an estimated 216,000 – 600,000 deaths per year, predominantly in children of school age or 
younger (1, 2, 9). 
WHO estimates the annual global rate of typhoid fever at 2 million with a 1-4% fatality rate. An estimated 90% of 
these deaths occur in Asia. Increasing multidrug resistance of S. typhi reduce the effective treatment options, increase 
treatment cost and results in higher rates of serious complication and death. 
Two new generation vaccines have replaced the old reactogenic inactivated whole cell vaccine used in the past. 
These new generation vaccine are the injectable Vi polysaccharide vaccine and the live oral Ty21a and have been 
shown in large-scale clinical trials. 
Vi is a linear homopolymer of Į (1-4)-D-GalpA N-acetylated at C-2 and O-acetylated at C-3 (3,4,5). The N and O-
acetyls dominate the surface and are essential for both antigenicity and immunogenicity of Vi (5,6). Vi antigen is a 
virulence factor which by itself is capable of conferring protection from infection with S typhi and Vi is present in most 
isolates from blood of patients with typhoid fever. The Vi antigen is immunogenic when injected intramuscularly or 
subcutaneously and confers protective immunity for at least 3 years (7). 
3rd  Vaccine Global Congress, Singapore 2009 
Sudeep Kothari et al. / Procedia in Vaccinology 2 (2010) 78–81 79
The cost of treatment of the typhoid fever is high and puts a lot of pressure on the financial resources of people in 
living in developing countries. Vaccination can help to reduce the disease burden but the vaccine must be affordable, so 
to address this problem a simple reliable and cost effective method to produce Vi was developed. The method 
eliminates the use of phenol and also results in a significant improvement in the purity of the bulk Vi without the need 
to use chromatographic methods.  
2. Material and Method 
S. typhi Ty2 strain was from ATCC and the wild type isolate C6524 strain was obtained from NICED Kolkata, 
India. S. typhi growth media consisted of yeast extract (Oxoid) 10 g/l, casamino acid (BD) 5g/l, MgSO4.7 H2O (USB) 
1.75g/l, Na2HPO4.7H2O (USB) 18.8g/l, NaH2PO4.H2O (USB) 4.1g/l, Glucose (Junsei) 3g/l, pH adjusted to 7.2 NaOH 
(8). Ty2 and C6524 were cultivated in growth media in shaker flasks prior to seeding the fermentors, an OD600 of about 
0.7 was achieved in the shaker flasks. The shaker flask cultures were seeded into 5L bioreactors (Biostat B-DCU, 
Sartorius) containing 2.5 L of growth media. Fermentation was performed with a pH control at 7.2, aeration at 0.8vvm, 
temperature control at 32°C, dissolved oxygen control at 35% with stirrer cascade and glucose concentration was 
maintained to 1g/l by step wise addition of feed solution (yeast extract 100 g/l, casamino acids 100 g/l, glucose 300 
g/l). Fermentation was approximately 14 hours including a 2 hour stationary phase. During the stationary phase the 
feed and aeration were stopped and culture is stirred at a fixed 200rpm. The culture broth was harvested after 
inactivation with 3.76 ml/l formalin and stored at 2-8°C prior to purification. 
The inactivated culture broth was clarified through a 0.45µm Hydrosart (Sartorius) cross flow cassette, the bacterial 
cells were concentrated 8 fold then diafiltered against 10 volume changes of 1M NaCl. The permeate containing the 
crude Vi was concentrated 10 fold and diafiltered against 8 volume changes of water using a 30kD Hydrosart 
(Sartorius) cassette. The Vi was then precipitated by reacting with Cetavlon at a final concentration of 0.5% for 2 
hours. The Vi precipitate was separated from the supernatant then washed with 20% ethanol. The washed precipitate 
was dissolved in 60% ethanol. 5M NaCl was added to the final concentration of 1M and the ethanol concentration 
increased to 75% by addition of absolute ethanol. The precipitated Vi was allowed to settle overnight and the clear 
supernatant removed by decantation. The precipitate was washed with absolute ethanol, the ethanol removed and the 
precipitate dissolved in water. Remaining impurities were precipitated with ammonium sulphate solution to the final 
concentration of 8%. Precipitated impurities were removed by filtration through a 0.2µm filter. The filtrate was 
concentrated 6 fold using a 100 kD Hydrosart (Sartorius) cross flow cassette and diafiltered against 20 volume changes 
water to remove residual ammonium sulphate. The final purified bulk concentrated Vi was filter sterilized through a 
0.2µm Sartopore 2 (Sartorius) sterilizing grade filter.    
3. Results 
The comparison of growth of Ty2 and C6524 is shown in fig.1 and clearly shows that Ty2 achieved a higher OD600
than did the C6524 isolate. Although the cell density as measured by OD600 was higher with Ty2 the production of Vi 
was greater with C6524. The Vi concentration in the Ty2 harvest culture broth as measured by ELISA was 452 mg/ml 
whereas the Vi concentration in the C6524 harvest was greater than 50% higher at 696 mg/ml. The C6524 isolate 
therefore produced much more Vi per bacterial cell than did Ty2.  
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Figure 1: Growth curve of S. typhi Ty-2 strain (Ÿ) and wild type 
isolate C6524 (Ŷ) in fed batch culture under controlled 
fermentation conditions. 
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With the high yield of Vi from C6524 it was necessary to demonstrate that the Vi could be purified to a standard 
defined by the WHO requirements for Vi polysaccharide vaccine. Three consistency lots were run and Vi purified from 
each of the three lots. 
In process samples were measured for protein, nucleic acid and endotoxin (LPS) content to determine the 
effectiveness of each of the process steps. The initial clarification was necessary to separate the Vi from the cells, but 
the major removal of impurities was achieved in the cetavlon precipitation and washing of the precipitate steps. These 
steps had reduced the protein and endotoxin levels to below acceptable levels as defined by the WHO. The nucleic acid 
levels were also dramatically reduced but were still too high so it was necessary to introduce the ammonium sulphate 
precipitation step to lower the nucleic acid from around 100 µg nucleic acid per mg of Vi to an acceptable < 20 µg 
nucleic acid per mg of Vi 
A summary of the assay results of final bulks for the three consistency lots is presented is Table 1 and demonstrate 
that the method produces a product that consistently meets the WHO requirements for Vi polysaccharide vaccine. 
Table 1. Results of assays performed on final bulk Vi produced for three consistency runs. Percentage of each component is calculated on the dry 
weight of Vi polysaccharide after lyophilization 
Vi produced using this method was compared to Vi produced using phenol extraction in immunogenicity studies in 
mice. The immunogenicity of Vi produced using both methods was essentially equivalent, the new method inducing 
slightly higher Vi serum antibody responses in mice.  
4. Discussion 
The Ty2 variant of S. typhi was shown to grow to higher cell density than the local wild type isolate C6524 during 
fermentation, however the local isolate produced a considerably greater amounts of Vi in the culture supernatant. The 
combination of increased production of Vi with lower cell density made purification more efficient as less impurities 
per Vi had to be removed during the purification procedure. 
The method developed relies on a number of properties of the Vi. Precipitation of the Vi in the presence of cetavlon 
depends on the negative charge of the Vi molecule. The selective solubility of the Vi in various solvents such as 
ethanol was also exploited. Solubility of Vi and lack of solubility of contaminating nucleic acids at a specific 
concentration of ammonium sulphate was also used to increase purity. In addition to selective solubility separations 
were performed based on size and the selection of crossflow membranes was designed to maximize the removal of 
contaminants and at the same time maximize the recovery of the Vi. The final bulk Vi produced using this method can 
be sterilized by filtration which helps to assure the quality of the vaccine. 
The production of three consecutive lots demonstrated that the purification method was capable of consistently 
purifying Vi polysaccharide to meet the requirements of the WHO for Vi polysaccharide vaccine (9). The next step was 
to demonstrate that the method could be scaled up to production size and this has been subsequently demonstrated by 
our manufacturing partner in India. 
The method developed is consistent with GMP manufacture, the standard applied to producers of vaccines, and has 
also demonstrated that it can be used at production scale. Estimates from our laboratory scale manufacture indicate that 
a 100 litre bioreactor could produce around one million doses of vaccine (not allowing for losses or overfilling during 
the fill and finish into the final container). This very efficient high yielding method means that vaccine can be produced 
at low cost in the facilities of developing country vaccine manufacturers. This should then be translated into supply of 
affordable vaccines to those in most need of typhoid vaccine, the people living in poverty in typhoid endemic settings. 
Batch number Protein 
(%) 
Nucleic acid 
(%) 
O-acetyl 
(mmol/g Vi) 
Vi ELISA 
(mg/ml) 
Endotoxin 
(EU/µg of Vi) 
WHO requirement <1 <2 2.0 NA 25 
Run 1 0.1 1.6 2.2 2.6 2.3 
Run 2 0 0.3 2.1 2.4 3.9 
Run 3 0 0.7 2.3 1.9 3.7 
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Technology transfer of this method has now been completed to our partner vaccine company in India, Shantha 
Biotechnics. Clinical trials have been scheduled for licensure and introduction of either the Vi polysaccharide vaccine 
alone or a newer generation Vi conjugate vaccine which utilizes the Vi as the protective antigen. 
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